Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Literature DB >> 27817846

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

Panos Zanos¹, Ruin Moaddel², Patrick J Morris³, Irving W Wainer⁴, Edson X Albuquerque⁵, Scott M Thompson⁶, Craig J Thomas³, Carlos A Zarate⁷, Todd D Gould⁸.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 27817846 PMCID： PMC5359040 DOI： 10.1016/j.biopsych.2016.08.039

Source DB: PubMed Journal: Biol Psychiatry ISSN： 0006-3223 Impact factor: 13.382

× No keyword cloud information.

22 in total

1. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors: Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal: Science Date: 2010-08-20 Impact factor: 47.728

2. A double-blind, placebo-controlled study of memantine in the treatment of major depression.

Authors: Carlos A Zarate; Jaskaran B Singh; Jorge A Quiroz; Georgette De Jesus; Kirk K Denicoff; David A Luckenbaugh; Husseini K Manji; Dennis S Charney
Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112

3. What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder.

Authors: Gerard Sanacora
Journal: JAMA Psychiatry Date: 2016-07-01 Impact factor: 21.596

4. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors: Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal: Biol Psychiatry Date: 2012-01-31 Impact factor: 13.382

5. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors: James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal: Biol Psychiatry Date: 2012-07-27 Impact factor: 13.382

6. Using deuterium in drug discovery: leaving the label in the drug.

Authors: Thomas G Gant
Journal: J Med Chem Date: 2013-12-02 Impact factor: 7.446

7. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors: Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal: J Clin Psychopharmacol Date: 2008-12 Impact factor: 3.153

8. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382

9. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.

Authors: Jaskaran B Singh; Maggie Fedgchin; Ella Daly; Liwen Xi; Caroline Melman; Geert De Bruecker; Andre Tadic; Pascal Sienaert; Frank Wiegand; Husseini Manji; Wayne C Drevets; Luc Van Nueten
Journal: Biol Psychiatry Date: 2015-11-03 Impact factor: 13.382

10. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.

Authors: G Sanacora; M A Smith; S Pathak; H-L Su; P H Boeijinga; D J McCarthy; M C Quirk
Journal: Mol Psychiatry Date: 2013-10-15 Impact factor: 15.992

9 in total

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine.

1. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

2. A double-blind, placebo-controlled study of memantine in the treatment of major depression.

3. What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder.

4. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

5. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

6. Using deuterium in drug discovery: leaving the label in the drug.

7. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

8. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

9. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.

10. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.

Review 1. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

2. Effects of a ketamine metabolite on synaptic NMDAR function.

3. What's the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise?

Review 4. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Review 5. Convergent Mechanisms Underlying Rapid Antidepressant Action.

Review 6. Mechanisms of ketamine action as an antidepressant.

Review 7. Rodent ketamine depression-related research: Finding patterns in a literature of variability.

8. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.

9. Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients.